IGF2BP2 and neoplasm: This could also be a result of theprogram picking up phrases outside of a given context (i.e., biomarkervs target), though manual curation of data by subject matter expertshas ensured, where possible, that concepts picked out are pertinent.Among biomarkers, nectin-4,55 SET domaincontaining 2 (SETD2),56 ENO1,57 TROP2,58 tumor mutationburden (TMB),59 PCSK9,60 and LILRB161 appear to be growingat a fast pace, while p62,62 COX-2,63 and TDO64 show unremarkable/negligiblegrowth (Figure 2).